1244 (1244) Fair Value & Analysis

Healthcare · Market cap HK$603M

1 1244 1244 · HK

PriceHK$2.53

Fair ValueHK$0.6700

Upside-73.5%

Quality36/100

Evidence: Low Range HK$0.4400 – HK$0.8400

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −25.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$2.53 – HK$9.50 · fair‑value band HK$0.4400 – HK$0.8400 · the HK$2.53 price screens above the HK$0.6700 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1244 (1244) currently trades at HK$2.53, while our model-based Fair Value estimate is HK$0.6700 — implying the stock looks roughly 73.5% overvalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 1244 generated revenue of HK$356M at a net margin of -49.9%. Revenue declined 38.6% year over year. It earns a return on equity of -29.6%. The balance sheet holds a net cash position of HK$17.5M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$356M

Revenue growth (YoY) -38.6%

Net margin -49.9%

Return on equity -29.6%

Free cash flow −HK$150M FY2025

Operating margin -69.5%

More key figures

EPS (TTM) HK$-0.3600

Net cash HK$17.5M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1244 reported revenue of HK$356M in FY2025 versus HK$60.3M in FY2021, a compound +55.9%/yr. Reported net income was −HK$178M in FY2025.

Revenue +55.9%/yr

FY21 HK$60.3M

FY22 HK$567M

FY23 HK$635M

FY24 HK$446M

FY25 HK$356M

Net income

FY21 −HK$1.4B

FY22 −HK$1.0B

FY23 −HK$525M

FY24 −HK$183M

FY25 −HK$178M

Is 1244 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	7,746 MXN	449.62 MXN	-94%
Regeneron Pharmaceuticals, Inc REGN	$635.45	$547.01	-14%
UCB SA UCB	€274.90	€211.40	-23%
argenx SE ARGNF	$900.00	$382.64	-57%
Alnylam Pharmaceuticals, Inc ALNY	$291.22	$111.44	-62%
Samsung Biologics Co 207940	1,000,000 KRW	1,091,384 KRW	+9%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1244 (1244) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.6700 versus a price of HK$2.53 — about −74% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1244?

Our model-based fair value for 1244 is HK$0.6700 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.53.

What is the quality score of 1244?

1244 has a Quality Score of 36/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1244 (1244)?

1244 reported trailing-twelve-month revenue of about HK$356M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1244?

The net profit margin of 1244 is about -49.9%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.